Benzinga | Nov 2, 2021 10:50AM EDT

RBC Capital Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $119

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and lowers the price target from $130 to $119.